Rockefeller Capital Management’s Benitec Biopharma BNTC Stock Holding History

Rockefeller Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.79K	Hold	582	–	–	﹤0.01%	4107
2026 Q1	$6.2K	Buy	+582	New	+$6.74K	﹤0.01%	4183
2023 Q1	–	Sell	-18	Closed	–	–	2209
2022 Q4	$0	Hold	18	–	–	﹤0.01%	3864
2022 Q3	$0	Hold	18	–	–	﹤0.01%	3892
2022 Q2	$0	Hold	18	–	–	﹤0.01%	4104
2022 Q1	$0	Hold	18	–	–	﹤0.01%	3871
2021 Q4	$0	Hold	18	–	–	﹤0.01%	3774
2021 Q3	$1K	Hold	18	–	–	﹤0.01%	3539
2021 Q2	$1K	Hold	18	–	–	﹤0.01%	3310
2021 Q1	$1K	Hold	18	–	–	﹤0.01%	3156
2020 Q4	$0	Hold	18	–	–	﹤0.01%	2854
2020 Q3	$1K	Buy	+18	New	+$2.17K	﹤0.01%	2450

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Rockefeller Capital Management's BNTC Position: Q2 2026 in Review

Rockefeller Capital Management held its Benitec Biopharma (BNTC) position steady in Q2 2026 at 582 shares worth $7.79K. The position accounts for ﹤0.01% of the portfolio, ranked #4107.

Rockefeller Capital Management first reported a position in BNTC in Q3 2020 and has held it in 12 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

Rockefeller Capital Management held 582 shares of Benitec Biopharma worth $7.79K as of Q2 2026.
Rockefeller Capital Management left its Benitec Biopharma share count unchanged in Q2 2026.
Benitec Biopharma made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4107 holding.
Rockefeller Capital Management first reported a position in Benitec Biopharma in Q3 2020 and has held it in 12 quarters since.
87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.